Weekly Incretin Analog Dosing for Glycemic Control and GI Tolerability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes mellitus (T2DM) using GCG, GLP-1, and GIP tri-receptor agonists face challenges with gastrointestinal adverse events and sub-optimal glycemic control due to prolonged activity, leading to compliance issues and ineffective dose administration.
Innovation Solution
Optimized doses and dosing regimens for a GGG tri-receptor agonist (SEQ ID NO:1) ranging from 0.5 mg to 12.0 mg, administered weekly with adjustable increments and fixed schedules to achieve effective glycemic control and weight management while minimizing adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of GGG tri-receptor agonist are administered to achieve effective glycemic control, then glycemic control improves, but gastrointestinal adverse events increase
Solution Approach 1:
The patent segments the dosing regimen into multiple stages: an initial low dose (0.25-2 mg) for the first injection, followed by intermediate doses (2-8 mg) for subsequent injections, and finally a target dose (4-12 mg) for maintenance. This segmentation allows gradual acclimatization of the gastrointestinal system while progressively achieving effective glycemic control.
Solution Approach 2:
The patent implements preliminary action by administering a reduced initial dose before progressing to higher therapeutic doses. This preliminary low-dose injection prepares the patient's system in advance, reducing the likelihood of severe gastrointestinal adverse events when higher effective doses are subsequently administered.
2Ease of operation
If prolonged activity agonists are used to reduce injection frequency, then patient compliance improves, but steady-state activity is delayed
Solution Approach 1:
The patent employs periodic action with a once-weekly dosing schedule that maintains prolonged activity throughout the week. This periodic administration ensures consistent drug presence in the system, achieving both improved patient compliance through reduced injection frequency and relatively quick attainment of steady-state activity levels.
Solution Approach 2:
The patent utilizes parameter changes by adjusting the dose amount across different injection stages while maintaining the once-weekly dosing interval. This allows optimization of both the prolonged activity duration and the speed of reaching steady state by modifying the dosage parameter rather than the dosing frequency.
3Object-affected harmful factors
If dose increments are implemented to reduce adverse events, then tolerability improves, but time to reach effective dose increases
Solution Approach 1:
The patent implements dynamics by creating a flexible, adaptive dosing regimen that can be customized based on individual patient response. The dosing schedule dynamically adjusts from initial low doses through intermediate doses to target effective doses, allowing patients to reach effective therapy faster while maintaining tolerability through personalized progression rates.
Solution Approach 2:
The patent incorporates feedback mechanisms by monitoring patient response and tolerability at each dosing stage, allowing clinicians to adjust the progression rate and dose increments accordingly. This feedback-driven approach enables patients to reach effective doses efficiently while minimizing adverse events based on individual tolerability patterns.
Data Source
AI summary
Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.